Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

 Blogroll
Fujitsu Siemens Computers Reveals A Green, Sustainable Future

Fujitsu Siemens Computers Reveals A Green, Sustainable Future

Jan 31 2008 | comment(s)

MUNICH, Germany, January 31 /PRNewswire/ --

- Company First to Offer Complete Product Range Balancing Business Performance With Environmental Care

Fujitsu Siemens Computers executives outlined the company's strategic commitment to environmental sustainability in a podcast released today and available at http://www.prnewswire.com/mnr/fujitsu-siemens/31527/.

Bernd Bischoff, chief executive officer, said: "I'm proud we're the first IT vendor with a complete range of environmentally sound products for the data centre, in the office, on the move and at home."

Green at heart

Hatstand Joins The Open MiFID Alliance

Hatstand Joins The Open MiFID Alliance

Jan 31 2008 | comment(s)

Oncolytics Biotech Inc. Proceeds To Full Enrolment In U.S. Phase II Sarcoma Clinical Trial

Oncolytics Biotech Inc. Proceeds To Full Enrolment In U.S. Phase II Sarcoma Clinical Trial

Jan 31 2008 | comment(s)

CALGARY, Canada, January 31 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has met the initial criteria to proceed to full enrolment in its U.S. Phase II trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung.

B Roll Available Of Royal Dutch Shell 2007 Q4 Results Presentation

B Roll Available Of Royal Dutch Shell 2007 Q4 Results Presentation

Jan 31 2008 | comment(s)

THE HAGUE, The Netherlands, January 31 /PRNewswire/ -- Royal Dutch Shell plc releases its 2007 Q4 financial results on the morning of Thursday 31st January 2008.

To assist broadcasters, B Roll footage of the results presentation and Chief Executive, Jeroen van der Veer, is now available from BMC via a broadcast feed via BT Tower and on Beta SP tape.

The broadcast feed will be: Date: 31st January Time: 10:30 - 11:00 gmt (11:30 - 12:00 CET) Available from BT Tower - Circuit FL/GNE 23 or via satellite: W1 XP B3 CH-E 9MHz Ku Satellite U/L: 14,379.50 Y D/L: 11,079.50 X FEC: 3/4 Sym: 6.1113 Enc: GIR UKI Tel 1 GIR IRD14 - RX1290 Ku D/L & Space 9MHz

Amsterdam Molecular Therapeutics To Appoint Philippe Van Holle (Celgene) To Supervisory Board

Amsterdam Molecular Therapeutics To Appoint Philippe Van Holle (Celgene) To Supervisory Board

Jan 31 2008 | comment(s)

ILOG Announces 2008 Second Quarter Results

ILOG Announces 2008 Second Quarter Results

Jan 31 2008 | comment(s)

PARIS and SUNNYVALE, California, January 31 /PRNewswire/ --

ILOG(R) (Nasdaq: ILOG; Euronext: ILO, ISIN: FR0004042364) today announced results for the second quarter of fiscal 2008, ended December 31, 2007, highlighted by 22% revenue growth year-over-year. Revenues for the quarter were US$48.0 million compared with US$39.4 million for the second quarter last year. U.S. GAAP earnings per share were US$0.15 compared with US$0.05 last year.